Clinical Trials in Suresnes, Île-de-France Region
2 recruiting
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
HER2 MutationAdvanced Non-Small Cell Lung Cancer
Bayer278 enrolled283 locationsNCT06452277
Recruiting
Not Applicable
Interest of Late Images for the Assessment of Extensions in 18FGD PET-CT of Muscle-Invasive Bladder Cancers
Muscle-Invasive Bladder CarcinomaBladder Cancer
Hopital Foch66 enrolled1 locationNCT06537960